Trial Profile

A Randomised, Double-Blind, Placebo-Controlled, Single Dose Trial Evaluating Different Doses of Intravenously Administered VMX-C001 and to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of VMX-C001 in Healthy Subjects (Part 1) and in Combination With a Selected FXa Direct Oral Anticoagulant (DOAC) in Healthy Older Subjects (Part 2)

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 22 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Recombinant coagulation factor X VarmX (Primary) ; Apixaban; Edoxaban; Rivaroxaban
Indications Haemorrhage
Focus Adverse reactions; Pharmacokinetics
Sponsors VarmX

23 Jul 2024 Planned End Date changed from 1 Sep 2024 to 1 Aug 2026.
23 Jul 2024 Planned primary completion date changed from 1 Sep 2024 to 1 Aug 2024.
23 Jul 2024 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com